חזרה לתוצאות החיפוש

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Generalized Myasthenia Gravis

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Neuromuscular Research Center, Phoenix, Arizona, United States

    Contact: Study coordinator (Lucia Rodriguez) · nrsresearch@nrcaz.com
    Contact: Principal Investigator (Kumaraswamy Sivakumar)

  • Honor Health Research Institute, Scottsdale, Arizona, United States

    Contact: Study coordinator (Kristy Osgood) · kosgood@honorhealth.com · 480-323-3990
    Contact: Principal Investigator (Anne Hatch)

  • Fullerton Neuro and Headache Ctr, Fullerton, California, United States

    Contact: Study coordinator (Alexandra Vasquez) · avasquez@fullertonneuro.net · 714-738-0800
    Contact: Principal Investigator (Jack H Florin)

  • University Of Southern California, Los Angeles, California, United States

    Contact: Study coordinator (Nasrin Ahmed) · nahmed@advmedresearch.com · 323-865-3900
    Contact: Principal Investigator (Said R Beydoun.)

  • Univ Cali Irvine ALS Neuromuscular, Orange, California, United States

    Contact: Study coordinator (Karina Bjazevic) · kbjazevi@hs.uci.edu · 714-456-2332
    Contact: Principal Investigator (Ali Habib)

  • California Pacific Medical Center, Sacramento, California, United States

    Contact: Study coordinator (Daniela Sanchez) · daniela.sanchez@sutterhealth.org · 415-600-3604
    Contact: Principal Investigator (Liberty Jenkins)

  • Medstar Washington Hospital Center, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Anu Bhooshan) · anu.r.bhooshan@medstar.net
    Contact: Principal Investigator (Nicholas Streicher)

  • SFM Clinical Research LLC, Boca Raton, Florida, United States

    Contact: Study coordinator (Gabrielle Demaria) · Gabrielle@sfmresearch.com · 561-939-0300
    Contact: Principal Investigator (Marc Feinberg)

  • Homestead Assoc In Research Inc, Homestead, Florida, United States

    Contact: Study coordinator (Daydene Ordaz) · dordaz@associatesinresearch.com · 305-246-0873
    Contact: Principal Investigator (Christopher Jimenez)

  • Neurology Associates PA, Maitland, Florida, United States

    Contact: Study coordinator (Kelly Holley) · admin@naparesearch.com · 407-647-5996
    Contact: Principal Investigator (Arnaldo Isa)

  • AdventHealth, Orlando, Florida, United States

    Contact: Study coordinator (Samuel Pierre Louis) · samuel.pierrelouis@adventhealth.com · +1 407 303 6729
    Contact: Principal Investigator (Anita Fletcher)

  • Neurological Services of Orlando PA, Orlando, Florida, United States

    Contact: Study coordinator (Tanya Palafox) · tanya.nso@outlook.com · 941-400-4578
    Contact: Principal Investigator (Daniel H Jacobs)

  • University of Chicago Medical Centr, Chicago, Illinois, United States

    Contact: Study coordinator (Deekshitha Turaka) · deekshitha.turaka@bsd.uchicago.edu
    Contact: Principal Investigator (Kourosh Rezania)

  • Mid Atlantic Epilepsy and Sleep Ctr, Bethesda, Maryland, United States

    Contact: Study coordinator (Arkady Barber) · barbera@epilepsydc.com
    Contact: Principal Investigator (Jonathan Ross)

  • Neuromuscular Diagnostic Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Isaac McCarthy) · imccarthy2@mgh.harvard.edu · 617-726-8736
    Contact: Principal Investigator (Amanda Guidon)

  • Michigan State University-Department of Neurology, East Lansing, Michigan, United States

    Contact: Study coordinator (Aubrey Alexander) · alexaub@msu.edu
    Contact: Principal Investigator (Amit Sachdev)

  • Dent Neurological Institute, Buffalo, New York, United States

    Contact: Study coordinator (Anna Mattle) · amattle@dentinstitute.com · 716-887-4799
    Contact: Principal Investigator (Bennett Myers)

  • Univ of Cincinnati Medical Center, Cincinnati, Ohio, United States

    Contact: Study coordinator (Kaiya Payne) · payne2ka@ucmail.uc.edu · 513-475-8730
    Contact: Principal Investigator (Hani Kushlaf)

  • Cleveland Clinic Foundation, Cleveland, Ohio, United States

    Contact: Study coordinator (Debbie Hastings) · hastind@ccf.org
    Contact: Principal Investigator (Yuebing Li)

  • University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Gabriela Niizawa) · niizawaga@upmc.edu · 412-692-4920
    Contact: Principal Investigator (Fang Sun)

  • Houston Methodist Hospital, Houston, Texas, United States

    Contact: Study coordinator (Delrose Vernon) · davernon@houstonmethodist.org · 713-441-9484
    Contact: Principal Investigator (Ericka Greene)

  • UT Health Science Center, Houston, Texas, United States

    Contact: Study coordinator (Ari Broussard) · ari.broussard@uth.tmc.edu
    Contact: Principal Investigator (Thy Nguyen)

  • University of WA Division of Cardio, Seattle, Washington, United States

    Contact: Study coordinator (Kaycie Opiyo) · tkaycie@uw.edu · 206-685-1048
    Contact: Principal Investigator (Barbara Jane Distad)

  • Center for Neurological Disorders G, Greenfield, Wisconsin, United States

    Contact: Study coordinator (Emily Barraza) · Emily.barraza@cndmilwaukee.com
    Contact: Principal Investigator (Bhupendra Khatri.)

  • Novartis Investigative Site, Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, Capital Federal, Argentina

  • Novartis Investigative Site, San Miguel de Tucumán, Argentina

  • Novartis Investigative Site, Kogarah, New South Wales, Australia

  • Novartis Investigative Site, Fitzroy, Victoria, Australia

  • Novartis Investigative Site, Southport, Australia

  • Novartis Investigative Site, Leuven, Vlaams Brabant, Belgium

  • Novartis Investigative Site, Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site, Brasília, Federal District, Brazil

  • Novartis Investigative Site, Caxias do Sul, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, São Paulo, Brazil

  • Novartis Investigative Site, Edmonton, Alberta, Canada

  • Novartis Investigative Site, London, Ontario, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Hefei, Anhui, China

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Shijiazhuang, Hebei, China

  • Novartis Investigative Site, Zhengzhou, Henan, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Wuxi, Jiangsu, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Qingdao, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Bordeaux, France

  • Novartis Investigative Site, Nice, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Strasbourg, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Kutaisi, Georgia

  • Novartis Investigative Site, Tbilisi, Georgia

  • Novartis Investigative Site, Tbilisi, Georgia

  • Novartis Investigative Site, Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site, Gummersbach, Germany

  • Novartis Investigative Site, Hamburg, Germany

  • Novartis Investigative Site, Münster, Germany

  • Novartis Investigative Site, Gurugram, Haryana, India

  • Novartis Investigative Site, Mangalore, Karnataka, India

  • Novartis Investigative Site, Nashik, Maharashtra, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, Ludhiana, Punjab, India

  • Novartis Investigative Site, Vellore, Tamil Nadu, India

  • Novartis Investigative Site, Hyderabad, Telangana, India

  • Novartis Investigative Site, Lucknow, Uttar Pradesh, India

  • Novartis Investigative Site, Bergamo, BG, Italy

  • Novartis Investigative Site, Orbassano, TO, Italy

  • Novartis Investigative Site, Naples, Italy

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Nishinomiya, Hyōgo, Japan

  • Novartis Investigative Site, Hanamaki, Iwate, Japan

  • Novartis Investigative Site, Sendai, Miyagi, Japan

  • Novartis Investigative Site, Suita, Osaka, Japan

  • Novartis Investigative Site, Higashi-Matsuyama, Saitama, Japan

  • Novartis Investigative Site, Koshigaya, Saitama, Japan

  • Novartis Investigative Site, Shinjuku Ku, Tokyo, Japan

  • Novartis Investigative Site, Chiba, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Fukushima, Japan

  • Novartis Investigative Site, Hiroshima, Japan

  • Novartis Investigative Site, Lublin, Lublin Voivodeship, Poland

  • Novartis Investigative Site, Lublin, Lublin Voivodeship, Poland

  • Novartis Investigative Site, Krakow, POL, Poland

  • Novartis Investigative Site, Bydgoszcz, Woj Kujawsko Pomorskie, Poland

  • Novartis Investigative Site, Bydgoszcz, Poland

  • Novartis Investigative Site, Katowice, Poland

  • Novartis Investigative Site, Lodz, Poland

  • Novartis Investigative Site, Lublin, Poland

  • Novartis Investigative Site, Lublin, Poland

  • Novartis Investigative Site, Poznan, Poland

  • Novartis Investigative Site, Rzeszów, Poland

  • Novartis Investigative Site, Skorzewo, Poland

  • Novartis Investigative Site, Szczecin, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Brasov, Romania

  • Novartis Investigative Site, Bucharest, Romania

  • Novartis Investigative Site, Sibiu, Romania

  • Novartis Investigative Site, Belgrade, Serbia

  • Novartis Investigative Site, Niš, Serbia

  • Novartis Investigative Site, Novi Sad, Serbia

  • Novartis Investigative Site, Busan, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Lleida, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Málaga, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Kaohsiung City, Taiwan

  • Novartis Investigative Site, Tainan, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Taoyuan, Taiwan

  • Novartis Investigative Site, London, United Kingdom

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)